Activating mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) occur in approximately 82–87% of patients with GIST [3], making these tumors amenable to treatment with tyrosine kinase inhibitors (TKIs). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.